Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.

Slides:



Advertisements
Similar presentations
Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy.
Advertisements

Non-Hodgkin’s Lymphoma
Non Hodgkin’s lymphoma
An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.
Heather D. Mannuel, MD, MBA March 12, 2008
Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.
There are many ways to slice the “lymphoma pie”. Simplified classification of NHLs Indolent (low grade) Aggressive (intermediate grade) Highly aggressive.
Acute leukemia Mohammed Al-matrafi.
Introduction To Haematological Malignancies
LYMPHOMAS By DR : Ramy A. Samy.
 Staging  Prognostic assessment  Formulation of a treatment plan (either curative or palliative)
Proposed WHO Classification of Lymphoid neoplasm
Supervisor: Vs 楊慕華醫師 Presenter: CR 周益聖醫師 N Engl J Med 2012;367:
By the end of this session you should know:
Chronic lymphocytic leukemia (1)
LYMPHOMA.
Chronic Lymphocytic Leukemia (CLL) DEFINITION CLL is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid.
Chronic Lymphocytic Leukemia. Definition Clonal B cell malignancy. Progressive accumulation of long lived mature lymphocytes. Increase in anti-apoptotic.
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
Non-Hodgkin’s lymphomas-definition and epidemiology
M. Mahmood Khan, MD Hematology-Oncology 12/5/03
Lymphomas Rowa’ Al-Ramahi.
Introduction to Low Grade Lymphomas Gena Piliotis.
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
Treatment of Leukemias and Lymphomas December 2013.
 Management varies with type of lymphoma and pt factors (co-morbidities, age, performance status, pt preferences)  Goal of tx can be curative, to prolong.
L YMPHOMA FOR THE G ENERALIST Lee Berkowitz, MD. G OALS AND O BJECTIVES 1. Understand the importance of pathology and staging in the approach to management.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
The sencond xiangya hospital,central south university
Treatment of B Cell Malignancies: Current and Emerging Strategies Thomas A. Rado, MD, PhD.
NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.
Malignancies of lymphoid cells ↑ incidence in general …. CLL is the most common form leukemia in US: Incidence in 2007: 15,340 Origin of Hodgkin lymphoma.
NON HODGKIN’S LYMPHOMA
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
NON HODGKIN’S LYMPHOMA Sec C Group D. NHL is a heterogenous group of lymphoproliferative malignancies with differing patterns of behavior and responses.
Lymphoma Rob Jones. Aim and learning outcomes Aim ◦ To revise the key points of lymphoma Learning outcomes ◦ Revise the basics of haemopoiesis ◦ Understand.
Chronic myeloid leukaemia( CML);. CML is an excessive proliferation with fairly normal maturation. The disease occurs mainly between 30 and 80 years with.
What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,
ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.
MLAB Hematology Keri Brophy-Martinez
White blood cells and their disorders Dr K Hampton Haematologist Royal Hallamshire Hospital.
Hematopoetic Cancers. Hematopoesis Leukemia New diagnoses each year in the US: 40, 800 Adults 3,500 Children 21,840 died of leukemia in 2010.
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
Low Grade Lymphomas: Treatment approaches Parameswaran Venugopal, MD Professor of Medicine Rush University Medical Center.
Treatment of non-Hodgkin Lymphomas
Non-Hodgkin Lymphoma March 13, 2013 Suzanne R. Fanning, DO Greenville Health System.
BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.
Lymphoma Most present as tumor Involving lymph nodes or other lymphoid organs such as the spleen. But extra nodal presentation may seen. Hodgkin’s Lymphoma.
NON-HODGKIN’S LYMPHOMA
Survey summary PTCL clinical practice recommendations
Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.
Campos M et al. Proc EHA 2013;Abstract B2009.
Non-Hodgkin’s Lymphoma
Campos M et al. Proc EHA 2013;Abstract B2009.
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
Lymphoma Most present as tumor Involving lymph nodes or other lymphoid organs such as the spleen. But extra nodal presentation may seen. Hodgkin’s Lymphoma.
Goede V et al. Proc ASH 2014;Abstract 3327.
Non-Hodgkin’s Lymphoma Thomas Kochuparambil 10/20/10
Stephen Ansell, MD, PhD Mayo Clinic
Pilot study of modified LMB-based therapy for children with ataxia telangiectasia and advanced stage high grade mature B-cell malignancies. Pediatr Blood.
What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,
Treatment guideline and algorithm for Advanced Stage Follicular and Nodal Marginal Zone* Lymphomas All patients should be considered for, and offered,
Lymphomas: Part II.
Gordon LI et al. Proc ASH 2010;Abstract 415.
Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin)
Neoplastic disorder.
Clinical Lymphoma, Myeloma and Leukemia
Optimizing therapy for nodal marginal zone lymphoma
Presentation transcript:

Treatment of Non- Hodgkin’s Lymphoma

Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High dose systemic therapy –Treatment to eliminate CNS disease Continuing therapy: prevent relapse and effect cure

Precursor B cell Lymphoblastic Leukemia Combination therapy used: –Rituximab- fludarabine- cyclophosphamide Associated with grade III or IV neutropenia –Cyclophophamide- vincristine- prednisone –Cyclophosphamide- doxorubicin- vincristine- prednisone

B Cell Chronic Lymphoid Leukemia/ Small Lymphocytic Leukemia Most common: –Chlorambucil: orally; few immediate side effects Chosen in elderly patients who require therapy –Fludarabine: IV; with significant immune suppression more active agent; with significant incidence of complete remission Regimens inclusive of this drug is chosen for young patients presenting with leukemiarequiring therapy Second line agent for patients with tumors unresponsive to chlorambucin

B Cell Chronic Lymphoid Leukemia/ Small Lymphocytic Leukemia Rai stage O and Binet stage A ( no manifestations of disease other than BM involvement and lymphocytosis –Followed without a specific therapy With adequate number of circulating normal blood cells, asymptomatic –Require treatment for the first few years of follow up

B Cell Chronic Lymphoid Leukemia/ Small Lymphocytic Leukemia Rai stage III or IV or Binet stage C (Bone Marrow failure) –Require initial therapy –Immune manifestations should be managed independently of antileukemic therapy

MALT Lymphoma Radiation and Surgery –Because it is often localized Eradication of H. pylori infection With more extensive diseases: Chlorambucil

Mantle Cell Lymphoma With disseminated disease: aggressive combination chemotherapy regimens+ autologous/ allogeneic BM transplantation Localized diseases: combination chemotherapy + radiotherapy Asymptomatic, elderly patient: observation + single- agent chemotherapy

Follicular Lymphoma Asymptomatic patient, older patient: watchful waiting For those who require treatment: single- agent chlorambucil or cyclophosphamide or combination therapy with CVP or CHOP For patients with localized follicular lymphoma: radiotherapy

Follicular Lymphoma Most responsive to chemotherapy and radiotherapy Active therapies: –Fludarabine –Interferon α: prolong survival in patients on doxorubicin- containing combination therapies –Monoclonal antibodies with or without radionuclides –Lymphoma vaccines

Diffuse Large B Cell Lymphoma Initial Treatmant: combination chemotherapy regimen= CHOP + Rituximab –Stage I or non bulky stage II: 3-4 cycles + field radiotherapy –Bulky stage II, stage III, stage IV: 6-8 cycles or 4 cycles then reevaluate -> complete remission -> 2 more cycles, then therapy discontinued

Diffuse Large B Cell Lymphoma IPI : predict favorable responses –Score 0-1: 5 year survival >70 % –Score 4-5: 5 year survival ~20% For refractory cases or relapse –Salvage therapy –Alternative combination therapy –Autologous bone marrow transplantation

Burkitt’s Lymphoma Treatment should begin 48 hrs after diagnosis High doses of cyclophosphamide Prophylactic therapy to CNS mandatory

Hairy cell leukemia: Cladribine Splenic marginal zone lymphoma: splenectomy, chlorambucil Lymphoplasmacytic lymphoma: Chlorambucil, fludarabine and cladribine Nodal marginal zone lymphoma: treatment same as follicular lymphoma

Precursor T Cell Lymphoblastic Leukemia Very intensive remission induction and consolidation regimens Leukemia- like regimens: for older children and young adults With high levels of LDH or BM, CNS involvement: BM transplantation

Anaplastic Large T/ Null Cell Lymphoma Treatment regimens same as for other aggressive lymphomas (diffuse large B cell lymphoma) Rituximab is omitted

Mycoises Fungoides –Localized early stage: radiotherapy- total skin electron beam irradiation –More advanced disease: topical glucocorticoids, topical nitrogen mustard, phototherapy, psoralen with PUVA, electron beam radiation, IFN, Antibodies, fusion toxins and systemic cytotoxic therapy Adult T Cell Lymphoma/ Leukemia –Combination chemotherapy regimens